ADC / XDC

Delve into the world of ADC / XDC in China’s pharmaceutical industry. Fineline Info & Tech provides reliable data, news, and insights on ADC / XDC to help you navigate complexities with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Pfizer's Hympavzi Wins NMPA Approval for a New Indication in China – World's First Once‑Weekly Non‑Factor Subcutaneous Therapy Extends to Hemophilia A and B with Inhibitors
CompanyDrug

Pfizer’s Hympavzi Wins NMPA Approval for a New Indication in China – World’s First Once‑Weekly Non‑Factor Subcutaneous Therapy Extends to Hemophilia A and B with Inhibitors

Pfizer Inc. (NYSE: PFE) announced that China's National Medical Products Administration (NMPA) has officially approved a new indication for Hympavzi (marstacimab) — the world's first non‑factor innovative therapy administered via…

Hybio Pharmaceutical's Oral HY3003 Tablets Clear NMPA Clinical Trial Application Acceptance – A Class 1 GLP‑1R/GIPR/GCGR Triple Agonist for Weight Loss, Type 2 Diabetes, and MASH

Hybio Pharmaceutical’s Oral HY3003 Tablets Clear NMPA Clinical Trial Application Acceptance – A Class 1 GLP‑1R/GIPR/GCGR Triple Agonist for Weight Loss, Type 2 Diabetes, and MASH

BeOne Medicines Reports Q3 2026 Global Revenues of USD 1.9 Billion, Up 34 % – BRUKINSA Tops USD 1.4 Billion as GAAP Net Income Reaches USD 385 Million

BeOne Medicines Reports Q3 2026 Global Revenues of USD 1.9 Billion, Up 34 % – BRUKINSA Tops USD 1.4 Billion as GAAP Net Income Reaches USD 385 Million

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
MSD Initiates IDeate-Prostate01 Phase III Trial of Ifinatamab Deruxtecan for mCRPC
CompanyDrug

MSD Initiates IDeate-Prostate01 Phase III Trial of Ifinatamab Deruxtecan for mCRPC

GlycoT Therapeutics Partners with Innovent Biologics to Advance ADC Technology
CompanyDeals

GlycoT Therapeutics Partners with Innovent Biologics to Advance ADC Technology

Shanghai Escugen and SunRock Biopharma Collaborate on First-in-Class CCR9-Targeted ADC
CompanyDeals

Shanghai Escugen and SunRock Biopharma Collaborate on First-in-Class CCR9-Targeted ADC

Simcere and NextCure Forge Strategic Alliance to Co-Develop SIM0505 ADC for Solid Tumors
CompanyDeals

Simcere and NextCure Forge Strategic Alliance to Co-Develop SIM0505 ADC for Solid Tumors

Escugen Partners with SovranBio to Accelerate Development of Antibody-Drug Conjugates
CompanyDeals

Escugen Partners with SovranBio to Accelerate Development of Antibody-Drug Conjugates

Daiichi Sankyo Launches Phase I Trial for Enhertu Subcutaneous Formulation
CompanyDrug

Daiichi Sankyo Launches Phase I Trial for Enhertu Subcutaneous Formulation

Hengrui Pharmaceuticals Launches Aiweida for HER2-Mutated NSCLC in China
CompanyDrug

Hengrui Pharmaceuticals Launches Aiweida for HER2-Mutated NSCLC in China

Sanyou Biopharma Partners with Medicovestor to Advance Next-Gen ADCs
CompanyDeals

Sanyou Biopharma Partners with Medicovestor to Advance Next-Gen ADCs

Show More